Boehringer Ingelheim Acquires T3 Pharma for $508.2M
Shots:
- The company announces the acquisition of T3 Pharma to expand its immuno-oncology Pipeline for the amount of $508.2M
- The purchase of T3 Pharma is complementary to several ongoing R&D initiatives & will greatly broaden the pipeline portfolio for immuno-oncology. This will get the company one step closer to realizing its goal of bringing about a paradigm change in the way that cancer is treated
- T3 Pharma has a novel platform that delivers bioactive proteins directly and selectively into the tumor microenvironment while protecting healthy tissues. This is achieved by employing genetically modified Yersinia enterocolitica bacteria
Ref: Boehringer | Image: Boehringer
Related News:- Boehringer Ingelheim’s Senvelgo Received the EC Approval in Europe for the Treatment of Feline Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
